US Stock Market Closed

Dashboard

10X Genomics, Inc. (TXG)

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

S

Industry Comparison

B

Management & Equity

B

Analyst Opinion

H

Leverage & Liquidity

B

Fundamental Variables

S

Rating Performance

FV Performance

*There is a current rating on the stock that is included in these numbers based on its performance so far

About

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company's products include Single Cell Gene Expression, Immune Profiling, CNV, ATAC, and Genome and Exome. 10X Genomics was founded by Serge Saxonov, Ben Hindson, Kevin D. Ness and Eduard Diviu Terradas on July 2, 2012 and is headquartered in Pleasanton, CA.

CEO

Serge Saxonov

Employees

584

Industry

Scientific Products

Sector

Healthcare

Headquarters

Pleasanton

Exchange

NASDAQ

Summary Stats

Market Cap

4.6B

Revenue

499M

Net Income

-89.1M

EPS

-$0.80

Price-to-Earnings

-61.22

Price-to-Book

5.7

Debt-to-Equity

0.24

News

Analyst Ratings

Price targets projected by 7 analysts

High

$165.00

Average

$148.57

Low

$135.00

Ratings calculated by 7 analysts

Buy

7

Hold

0

Sell

0

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q1 2022

Last Earnings

Missed by -$0.07

Actual

-$0.38 -22.6%

Consensus

-0.31

Report Date

Year Ago

-0.11

Year Ago Change %

Down 245%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites